disc medicine inc - IRON
IRON
Close Chg Chg %
80.43 -0.10 -0.12%
Closed Market
80.33
-0.10 (0.12%)
Volume: 218.07K
Last Updated:
Dec 26, 2025, 4:00 PM EDT
Company Overview: disc medicine inc - IRON
IRON Key Data
| Open $79.85 | Day Range 79.76 - 80.64 |
| 52 Week Range 30.82 - 99.50 | Market Cap $3.04B |
| Shares Outstanding 37.75M | Public Float 27.09M |
| Beta 0.86 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$5.36 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 647.23K |
IRON Performance
| 1 Week | 0.36% | ||
| 1 Month | -13.96% | ||
| 3 Months | 22.55% | ||
| 1 Year | 25.28% | ||
| 5 Years | -23.50% |
IRON Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About disc medicine inc - IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.
IRON At a Glance
Disc Medicine, Inc.
321 Arsenal Street
Watertown, Massachusetts 02472
| Phone | 1-617-674-9274 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -109,357,000.00 | |
| Sector | Health Technology | Employees | 84 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
IRON Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.268 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.959 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.023 |
IRON Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,301,869.048 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IRON Liquidity
| Current Ratio | 21.171 |
| Quick Ratio | 21.171 |
| Cash Ratio | 21.011 |
IRON Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -25.292 |
| Return on Equity | -27.731 |
| Return on Total Capital | -23.091 |
| Return on Invested Capital | -26.672 |
IRON Capital Structure
| Total Debt to Total Equity | 6.763 |
| Total Debt to Total Capital | 6.335 |
| Total Debt to Total Assets | 6.039 |
| Long-Term Debt to Equity | 6.734 |
| Long-Term Debt to Total Capital | 6.307 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Disc Medicine Inc - IRON
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 231.00K | 300.00K | 100.00K | 156.00K | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 231.00K | 300.00K | 100.00K | 156.00K | |
Depreciation
| 231.00K | 300.00K | 100.00K | 156.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +29.87% | -66.67% | +56.00% | |
Gross Income
| (231.00K) | (300.00K) | (100.00K) | (156.00K) | |
Gross Income Growth
| - | -29.87% | +66.67% | -56.00% | |
Gross Profit Margin
| - | - | - | - | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 69.07M | 47.17M | 91.03M | 129.56M | |
Research & Development
| 48.69M | 33.35M | 69.16M | 96.52M | |
Other SG&A
| 20.39M | 13.83M | 21.86M | 33.05M | |
SGA Growth
| +9,537.72% | -31.70% | +92.95% | +42.34% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 711.00K | 61.00K | 1.50M | |
EBIT after Unusual Expense
| (70.02M) | (47.54M) | (92.63M) | (129.72M) | |
Non Operating Income/Expense
| 305.00K | 709.00K | 16.30M | 21.29M | |
Non-Operating Interest Income
| 15.00K | 709.00K | 14.80M | 21.29M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 2.16M | 572.00K | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | 2.16M | 572.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (71.87M) | (46.83M) | (76.33M) | (109.00M) | |
Pretax Income Growth
| -8,745.47% | +34.84% | -63.00% | -42.80% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | 99.00K | 355.00K | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (71.87M) | (46.83M) | (76.43M) | (109.36M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (71.87M) | (46.83M) | (76.43M) | (109.36M) | |
Net Income Growth
| -8,745.47% | +34.84% | -63.22% | -43.08% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (71.87M) | (46.83M) | (76.43M) | (109.36M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (71.87M) | (46.83M) | (76.43M) | (109.36M) | |
EPS (Basic)
| -17.806 | -45.0481 | -3.4249 | -3.9614 | |
EPS (Basic) Growth
| -3,304.59% | -152.99% | +92.40% | -15.66% | |
Basic Shares Outstanding
| 4.04M | 1.04M | 22.32M | 27.61M | |
EPS (Diluted)
| -17.806 | -45.0481 | -3.4249 | -3.9614 | |
EPS (Diluted) Growth
| -3,304.59% | -152.99% | +92.40% | -15.66% | |
Diluted Shares Outstanding
| 4.04M | 1.04M | 22.32M | 27.61M | |
EBITDA
| (69.07M) | (47.17M) | (91.03M) | (129.56M) | |
EBITDA Growth
| -8,354.38% | +31.70% | -92.95% | -42.34% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 120.167 | |
| Number of Ratings | 13 | Current Quarters Estimate | -1.746 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -6.166 | |
| Last Quarter’s Earnings | -1.77 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.96 | Next Fiscal Year Estimate | -6.904 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 9 | 12 | 12 |
| Mean Estimate | -1.75 | -1.81 | -6.17 | -6.90 |
| High Estimates | -1.51 | -1.44 | -5.90 | -5.34 |
| Low Estimate | -2.07 | -2.20 | -6.51 | -9.03 |
| Coefficient of Variance | -8.87 | -15.31 | -2.60 | -17.04 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 12 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Disc Medicine Inc - IRON
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Disc Medicine Inc - IRON
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 17, 2025 | Polaris Growth Management LLC Director | 564,363 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.26 per share | 38,523,418.38 |
| Oct 17, 2025 | Polaris Growth Management LLC Director | 551,977 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.31 per share | 38,257,525.87 |
| Oct 17, 2025 | Polaris Growth Management LLC Director | 526,577 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70.54 per share | 37,144,741.58 |
| Oct 17, 2025 | Polaris Growth Management LLC Director | 513,888 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $71.51 per share | 36,748,130.88 |
| Oct 17, 2025 | Polaris Growth Management LLC Director | 500,621 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $72.39 per share | 36,239,954.19 |
| Oct 17, 2025 | Kevin J. Bitterman Director | 579,243 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $68.01 per share | 39,394,316.43 |
| Oct 17, 2025 | Polaris Growth Management LLC Director | 572,582 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $69.01 per share | 39,513,883.82 |
| Apr 9, 2025 | John D. Quisel Chief Executive Officer; Director | 208,420 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 9, 2025 | John D. Quisel Chief Executive Officer; Director | 161,828 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $1.01 per share | 163,446.28 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 487,676 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.01 per share | 26,339,380.76 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 187,297 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54 per share | 10,114,038.00 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 749,197 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54 per share | 40,456,638.00 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 484,264 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54 per share | 26,150,256.00 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 188,617 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.01 per share | 10,187,204.17 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 754,476 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.01 per share | 40,749,248.76 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 188,981 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.02 per share | 10,208,753.62 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 755,933 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.02 per share | 40,835,500.66 |
| Mar 24, 2025 | OrbiMed Advisors Private Equity Director | 488,617 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.02 per share | 26,395,090.34 |
| Feb 21, 2025 | Jean M. Franchi Chief Financial Officer | 69,530 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.58 per share | 3,794,947.40 |
| Feb 21, 2025 | Pamela Stephenson Chief Commercial Officer | 69,529 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $54.58 per share | 3,794,892.82 |